Related Experiment Videos
Sisomicin in the treatment of severe or complicated urinary tract infections
Abstract:
Sisomicin is a new aminoglycoside aminocyclitol antibiotic with pharmacological similarities to gentamicin and tobramycin. Fourteen of 24 patients with a severe or complicated urinary tract infection were cured by treatment with a 4-14 day course of sisomicin. In three patients the organism was not eliminated, in one there was a relapse with the same organism while in the remaining six patients a new pathogen (a gram-positive organism in five of these six) appeared within three to six days of completing the course of treatment. The initial infecting organism was therefore eradicated in 20 of the 24 patients treated. This drug should prove beneficial for the treatment of severe gram-negative sepsis.
Insights
Sisomicin effectively treated severe urinary tract infections in 20 of 24 patients. This new antibiotic showed promise for severe gram-negative sepsis, though secondary infections occurred in some cases.
Area of Science:
- Pharmacology
- Infectious Diseases
- Antibiotic Therapy
Background:
- Sisomicin is a novel aminoglycoside aminocyclitol antibiotic.
- It shares pharmacological properties with established antibiotics like gentamicin and tobramycin.
Purpose of the Study:
- To evaluate the efficacy of sisomicin in treating severe or complicated urinary tract infections.
- To assess the potential of sisomicin for treating severe gram-negative sepsis.
Main Methods:
- A treatment course of sisomicin (4-14 days) was administered to 24 patients.
- Patient outcomes, including pathogen eradication and secondary infections, were monitored.
Main Results:
- Twenty of 24 patients achieved initial eradication of the infecting organism.
- Fourteen patients were cured, while six developed new pathogens (five gram-positive).
- The drug demonstrated potential for treating severe gram-negative sepsis.
Conclusions:
- Sisomicin is effective in eradicating initial pathogens in most severe urinary tract infections.
- Further investigation into its role in treating severe gram-negative sepsis is warranted.
- Potential for secondary infections requires consideration during treatment.